Arrowhead Pharmaceuticals (ARWR) and Johnson & Johnson (JNJ) said Friday they eradicated nearly all traces of hepatitis B virus in a Phase 2 study — sending Arrowhead stock careening toward a record high. On the stock market today, Arrowhead stock jumped 6.3% to 42.10. On Monday, shares hit a record high in intraday action of 42.29. Arrowhead stock broke out on Oct. 17, topping a buy point at 36.90 out of a cup base. Now, the stock is roughly 14% extended. CAN SLIM rules for investing suggest taking some profits when a stock rises 20%-25% above its buy point.
Why It Could Soon Be Time To Take Profits In This Highflying Biotech Stock
By Michael Tattory|
2019-11-18T11:11:31-04:00
November 8th, 2019|News|Comments Off on Why It Could Soon Be Time To Take Profits In This Highflying Biotech Stock